| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| G E Davis, W E Lowell, G L Davi. Determining the number of state psychiatric hospital beds by measuring quality of care with artificial neural networks. American journal of medical quality : the official journal of the American College of Medical Quality. vol 13. issue 1. 1998-04-30. PMID:9509590. |
in studying specific diagnosis groups with the same methodology the authors found that patients with schizophrenia having the benefit of clozapine for most of the study period had a q averaged over 7 years that was nearly equal in both hospital and community settings. |
1998-04-30 |
2023-08-12 |
Not clear |
| H Y Meltze. Treatment-resistant schizophrenia--the role of clozapine. Current medical research and opinion. vol 14. issue 1. 1998-04-30. PMID:9524789. |
treatment-resistant schizophrenia--the role of clozapine. |
1998-04-30 |
2023-08-12 |
Not clear |
| E Schulz, C Fleischhaker, H W Clement, H Remschmid. Blood biogenic amines during clozapine treatment of early-onset schizophrenia. Journal of neural transmission (Vienna, Austria : 1996). vol 104. issue 10. 1998-04-29. PMID:9503259. |
blood biogenic amines during clozapine treatment of early-onset schizophrenia. |
1998-04-29 |
2023-08-12 |
human |
| E Schulz, C Fleischhaker, H W Clement, H Remschmid. Blood biogenic amines during clozapine treatment of early-onset schizophrenia. Journal of neural transmission (Vienna, Austria : 1996). vol 104. issue 10. 1998-04-29. PMID:9503259. |
finally, in responders to clozapine a negative linear relationship between negative symptoms of schizophrenia and the concentrations of plasma norepinephrine and serum serotonin were observed. |
1998-04-29 |
2023-08-12 |
human |
| D Eber. [Atypical neuroleptics--the future of schizophrenia treatment?]. Fortschritte der Medizin. vol 116. issue 3. 1998-04-28. PMID:9522541. |
whether clozapine is also capable of improving the primary negative symptoms of schizophrenia (e.g. |
1998-04-28 |
2023-08-12 |
Not clear |
| A K Malhotra, D Goldman, R W Buchanan, W Rooney, A Clifton, M H Kosmidis, A Breier, D Picka. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Molecular psychiatry. vol 3. issue 1. 1998-04-27. PMID:9491816. |
the dopamine d3 receptor (drd3) ser9gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. |
1998-04-27 |
2023-08-12 |
Not clear |
| A K Malhotra, D Goldman, R W Buchanan, W Rooney, A Clifton, M H Kosmidis, A Breier, D Picka. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Molecular psychiatry. vol 3. issue 1. 1998-04-27. PMID:9491816. |
these data suggest that allelic variation in drd3 may not play a role in the pathophysiology of schizophrenia or in clozapine response. |
1998-04-27 |
2023-08-12 |
Not clear |
| S E Purdon, M Snaters. Selective serotonin reuptake inhibitor modulation of clozapine effects on cognition in schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 1. 1998-04-22. PMID:9494753. |
selective serotonin reuptake inhibitor modulation of clozapine effects on cognition in schizophrenia. |
1998-04-22 |
2023-08-12 |
Not clear |
| G Bondolfi, H Dufour, M Patris, J P May, U Billeter, C B Eap, P Bauman. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. The American journal of psychiatry. vol 155. issue 4. 1998-04-22. PMID:9545995. |
risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. |
1998-04-22 |
2023-08-12 |
Not clear |
| W M Glazer, R A Dickso. Clozapine reduces violence and persistent aggression in schizophrenia. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541332. |
clozapine reduces violence and persistent aggression in schizophrenia. |
1998-04-10 |
2023-08-12 |
human |
| W M Glazer, R A Dickso. Clozapine reduces violence and persistent aggression in schizophrenia. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541332. |
the reduction in violence and persistent aggression with clozapine treatment should improve the chances for integration of the schizophrenia patient into the community and provide cost savings to society. |
1998-04-10 |
2023-08-12 |
human |
| H Y Meltze. Suicide in schizophrenia: risk factors and clozapine treatment. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541333. |
suicide in schizophrenia: risk factors and clozapine treatment. |
1998-04-10 |
2023-08-12 |
Not clear |
| D E Case. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541336. |
when clozapine became commercially available for treatment-resistant and treatment-intolerant (i.e., prone to eps and td) schizophrenic individuals, it became apparent that an antipsychotic need not induce motor side effects to be efficacious in reducing the symptomatology of schizophrenia. |
1998-04-10 |
2023-08-12 |
Not clear |
| J A Lieberma. Maximizing clozapine therapy: managing side effects. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541337. |
clozapine remains the only antipsychotic with proven efficacy in treatment-resistant schizophrenia. |
1998-04-10 |
2023-08-12 |
Not clear |
| R R Conle. Optimizing treatment with clozapine. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541338. |
clozapine is the only antipsychotic agent that is effective in treatment-resistant schizophrenia. |
1998-04-10 |
2023-08-12 |
Not clear |
| W T Carpenter, J M Zito, J Vitrai, J Volavk. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy? Biological psychiatry. vol 43. issue 2. 1998-04-03. PMID:9474440. |
how clozapine exerts superior antipsychotic efficacy in treatment-resistant schizophrenia is not known. |
1998-04-03 |
2023-08-12 |
Not clear |
| R Shiloh, Z Zemishlany, D Aizenberg, M Radwan, B Schwartz, P Dorfman-Etrog, I Modai, M Khaikin, A Weizma. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. The British journal of psychiatry : the journal of mental science. vol 171. 1998-04-03. PMID:9519099. |
sulpiride augmentation in people with schizophrenia partially responsive to clozapine. |
1998-04-03 |
2023-08-12 |
Not clear |
| A E Evins, E T Amico, V Shih, D C Gof. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. Journal of neural transmission (Vienna, Austria : 1996). vol 104. issue 6-7. 1998-03-10. PMID:9444574. |
to examine whether serum excitatory amino acid concentrations change with clozapine treatment and whether these changes correlate with improvement in negative symptoms, serum excitatory amino acids were measured and clinical scales administered in seven subjects with schizophrenia before and after switching from conventional neuroleptics to clozapine. |
1998-03-10 |
2023-08-12 |
human |
| D L Fogelson, H Sternbach, D Payn. A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. Journal of clinical psychopharmacology. vol 17. issue 6. 1998-02-06. PMID:9408817. |
a naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. |
1998-02-06 |
2023-08-12 |
Not clear |
| M D Combs, P J Perry, K A Beve. N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia. Pharmacotherapy. vol 17. issue 6. 1998-01-30. PMID:9399615. |
we reviewed the charts of 58 patients with treatment-refractory schizophrenia who were receiving clozapine, to determine if the drug's active metabolite, n-desmethylclozapine, is a biologic marker for impending clozapine-induced granulocytopenia and agranulocytosis. |
1998-01-30 |
2023-08-12 |
Not clear |